Oyster Point Pharma, Inc. OYST
Set alert
11.17 +11.17 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 299.85M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -3.50
- Beta
- 1.28
- Short ratio
- 1.54
- Inst. own
- 87.32%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 23, 2023
- 50-d avg
- 11.07
- 200-d avg
- 7.32
- 1y target
- 15.00
Key statistics
- Market cap
- 299.85M
- Enterprise value
- 325.77M
- Trailing P/E
- 0.00
- Forward P/E
- -3.50
- PEG ratio
- 0.00
- Price / sales
- 15.31
- Price / book
- 0.00
- EPS (TTM)
- -4.95
- Beta
- 1.28
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 19.58M
- Revenue growth
- -68.80%
- Free cash flow
- -97.05M
- Total cash
- 68.80M
- Total debt
- 94.72M
- Return on equity
- -306.38%
- Shares outstanding
- 26.84M
- Short % of float
- 2.04%
- 50-day average
- 11.07
- 200-day average
- 7.32
Analyst view
Consensus: hold
Hold
Price target (mean) 15.00 +34.3% upside
Now 11.17
- Target (low)
- 11.00
- Target (mean)
- 15.00
- Target (high)
- 22.00
Next earnings
Feb 23, 2023
Expected Feb 23, 2023. Consensus EPS estimate -1.26.
Financials — quick view
OYST Revenue — quarterly 5.59M
OYST Net income — quarterly -36.75M
OYST EPS — quarterly -1.37
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 23, 2023 | Dec 1, 2022 | -1.19 | — | — | — |
| Nov 10, 2022 | Sep 1, 2022 | -1.52 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | -1.64 | — | — | — |
| May 5, 2022 | Mar 1, 2022 | -1.75 | — | — | — |
| Feb 24, 2022 | Dec 1, 2021 | -1.39 | — | — | — |
| Nov 4, 2021 | Sep 1, 2021 | -1.16 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 8, 2022 | Chardan Capital | down | Buy | Neutral |
| Nov 8, 2022 | Piper Sandler | down | Overweight | Neutral |
| Aug 11, 2022 | Chardan Capital | init | — | Buy |
| Jul 18, 2022 | HC Wainwright & Co. | init | — | Buy |
| Nov 9, 2021 | JP Morgan | down | Overweight | Neutral |
| Nov 25, 2019 | JP Morgan | init | — | Overweight |
About Oyster Point Pharma, Inc.
As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- oysterpointrx.com
News
- OYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue Estimates
- Earnings Scheduled For November 10, 2022
- Why Viatris (VTRS) Is Buying Oyster Point (OYST)
- Oyster Point Pharma To Report Third Quarter 2022 Financial Results On November 10, 2022
- Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII
- Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium
- Oyster Point Pharma, Inc. (OYST) CEO Dr. Jeffrey Nau on Q2 2022 Results - Earnings Call Transcript
- OYSTER PT PHARM (OYST) Reports Q2 Loss, Lags Revenue Estimates
- Oyster Point Pharma To Report Second Quarter 2022 Financial Results On August 11, 2022
- This Healthcare Stock Jumped 110%; Here Are 64 Biggest Movers From Yesterday
Your note
Sign in to keep a note on OYST — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ATIEH MICHAEL G | Director | Stock Award(Grant) | Jun 5, 2022 | 26,734 |
| BEHBAHANI ALI | Director | Stock Award(Grant) | Jun 5, 2022 | 13,639 |
| ELIADES GEORGE CHRISTOPHER | Director | Stock Award(Grant) | Jun 5, 2022 | 28,624 |
| LOCHNER DANIEL J. | Chief Financial Officer | Stock Award(Grant) | Jan 6, 2022 | 77,721 |
| MURRAY MARK ANTHONY | Director | Stock Award(Grant) | Jun 5, 2022 | 122,086 |
| OZAWA CLARE | Director | Stock Award(Grant) | Jun 5, 2022 | 3,672,260 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| NEA Management Company, LLC | 22.07% | 5,925,287 | 66.19M | Sep 29, 2022 |
| Invus Financial Advisors, LLC | 10.31% | 2,768,586 | 30.93M | Sep 29, 2022 |
| RTW Investments LP | 7.62% | 2,044,312 | 22.83M | Sep 29, 2022 |
| Point72 Asset Management, L.P. | 6.73% | 1,805,387 | 20.17M | Sep 29, 2022 |
| Paradigm Biocapital Advisors LP | 6.14% | 1,648,316 | 18.41M | Sep 29, 2022 |
| Kohlberg Kravis Roberts & Co. L.P. | 3.87% | 1,039,622 | 11.61M | Sep 29, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.86% | 232,158 | 2.59M | Sep 29, 2022 |
| Fidelity Strategic Advisors Small-Mid Cap Fund | 0.76% | 203,167 | 2.27M | Sep 29, 2022 |
| John Hancock Fds II-New Opportunities Fund | 0.66% | 177,931 | 1.99M | Nov 29, 2022 |
| Vanguard Extended Market Index Fund | 0.64% | 171,624 | 1.92M | Sep 29, 2022 |
| BlackRock Advantage Small Cap Core Fund | 0.44% | 118,721 | 1.33M | Aug 30, 2022 |
| iShares NASDAQ Biotechnology ETF | 0.39% | 103,996 | 1.16M | Nov 29, 2022 |